American Society of Hirudotherapy

Catheter-Directed Bivalirudin for Local Anticoagulation and Clot Dissolution in Children Requiring Mechanical Circulatory Support

Chaudhry-Waterman N, Schardt TQ, Soderstrom RM, Warren BB, Buckvold S, Morgan G, Kim JS (2025) · ASAIO Journal · n=3

Observational study: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
GRADE Very LowCohort / case seriesBivalirudin: drug studies

Study Profile

Design
case series of three pediatric mechanical circulatory support patients receiving catheter-directed bivalirudin for localized thrombolysis (Children's Hospital Colorado)
Sample size (n)
3
Intervention
Direct bivalirudin delivery via catheter to localized intracardiac/circuit thrombosis in MCS patients
Main result
Direct bivalirudin delivery associated with rapid thrombus resolution in all three cases; novel application combining anticoagulant prevention with active fibrin-bound thrombin clearance
Follow-up duration
Acute MCS course

Key Findings

  • Case series of catheter-directed bivalirudin thrombolysis in pediatric mechanical circulatory support
  • All three cases achieved rapid thrombus resolution
  • Used in patients with alteplase contraindications (bleeding history)
  • Leverages bivalirudin's fibrin-bound thrombin inhibition
  • Novel application warranting larger series

Limitations

  • Only 3 cases - hypothesis-generating only
  • Single-center experience
  • No control comparison
  • Dosing not standardized for catheter-directed application
  • Not applicable to whole-leech hirudotherapy

Clinical Implications

Chaudhry-Waterman 2025 introduces novel catheter-directed bivalirudin use for localized thrombolysis in pediatric MCS patients. For ASH, this case series demonstrates the ongoing innovation cycle in the synthetic hirudin-derivative pharmaceutical pathway - new applications discovered through reasoning about mechanism (fibrin-bound thrombin inhibition). The K040187 device-leech US clinical practice operates under a more stable indication landscape without analogous novel-use innovation.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.